/
Other
Mortality
39
Pipeline Programs↗
18
Active Trials↗
17
Companies Involved↗
Mortality is a moderately active landscape with 39 programs across 17 companies. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical30
Phase 1
No programs
Phase 21
Phase 38
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
34 of 36 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 97% of 39 pipeline programs.
Analysis
Trial Status
103
clinical trials
Completed61 · 59%
Unknown status13 · 13%
Recruiting12 · 12%
Terminated9 · 9%
Active, not recruiting4 · 4%
Not yet recruiting2 · 2%
Other2 · 2%
Clinical Trials
Trial Activity
103 trials
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Recruiting·—·Phase 3·NCT05879276·164 enrolled
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
Recruiting·—·Phase 3·NCT04588311·2,500 enrolled
Infant Mortality Reduction by the Mass Administration of Azithromycin
Active, not recruiting·UUniversity of California, San Francisco·Phase 4·NCT04716712·694,400 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)